Press

ONL Therapeutics Announces Formation of Scientific Advisory Board

ONL Therapeutics Announces Formation of Scientific Advisory Board

October 14, 2015

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, is one of five of the world’s premier retinal disease thought leaders who will serve on its newly formed scientific advisory board (SAB).

Press for Boston KPro

September 1, 2015

Mass. Eye and Ear's Boston KPro was credited as the most widely used artificial cornea in an article from Ophthalmology Times on the use of bioengineered corneas.

September 1, 2015 Ophthalmology Times

Researchers Resurrect Ancient Viruses in Hopes of Improving Gene Therapy

Researchers Resurrect Ancient Viruses in Hopes of Improving Gene Therapy

July 30, 2015

Boston, MA Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina. This discovery, published July 30 in Cell Reports, could potentially be used to design gene therapies that are not only safer and more potent than therapies currently available, but may also help a greater number of patients.